Pharmaceutical News

RSS

Chiron flu vaccine banned for a further three months

The Chiron Corporation, a vaccine manufacturer, were told today that the suspension of their licence for manufacturing influenza vaccine at the Speke factory in Liverpool, would continue for a further three months.

8 Dec 2004

HHS purchases 1.2 million doses of GSK's Fluarix flu vaccine

HHS Secretary Tommy G. Thompson has announced that the Food and Drug Administration authorized the use of GlaxoSmithKline influenza vaccine, Fluarix, in the United States under an Investigational New Drug application.

8 Dec 2004

Escalating costs and lengthy clinical trials are major concerns for researchers in the field of drug discovery

Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.

7 Dec 2004

Prescription drug cost increases continuing to outpace inflation

A new report released today by AARP found the annual rate of manufacturers' price increases for the 197 brand name prescription drugs most commonly used by older Americans more than tripled the rate of inflation over the 12-month period ending on September 30, 2004.

6 Dec 2004

ID Biomedical announces strategic alliances for U.S. marketing and distribution of Fluviral vaccine

ID Biomedical Corporation announced today that it has signed long term marketing, distribution and minimum purchase agreements with three of the largest influenza vaccine wholesalers in the United States: Henry Schein, Inc.; AmerisourceBergen Corporation's Specialty Group; and McKesson Corporation.

6 Dec 2004

Review findings released on the safety of antidepressants (SSRI's)

The Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice to patients and doctors about the group of antidepressants known as SSRI's, today.

6 Dec 2004

Alliance to develop and commercialize fully-human anti-anthrax antibody

MDX-1303 was developed by Medarex using its UltiMAb Human Antibody Development System, and this antibody is currently in preclinical development by Medarex for use against human anthrax infection.

6 Dec 2004

Australian Government's decision to purchase sufficient influenza vaccine for the next three seasons is good health planning

Australian Medical Association Vice President, Dr Mukesh Haikerwal, has said the Australian Government's decision to purchase sufficient influenza vaccine for the next three seasons is good health planning.

6 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Pfizer submits regulatory filings for Revatio (sildenafil citrate) as a treatment for pulmonary arterial hypertension

Sildenafil is the active ingredient in Viagra, Pfizer's erectile dysfunction medication used by more than 23 million men worldwide.

4 Dec 2004

A vitamin B pill that drastically lowers blood levels of homocysteine could one day be used to prevent dementia

High blood levels of homocysteine are a risk factor for stroke and dementia, including Alzheimer’s disease. Raised levels damage nerves and blood vessels, and lead to a loss of brain tissue in patients.

4 Dec 2004

FDA approval of cream to treat bacterial vaginosis

KV Pharmaceutical Company has announced that it has received approval from the United States Food and Drug Administration (FDA) to market Clindesse (clindamycin phosphate) Vaginal Cream, 2%, a single-dose prescription cream therapy indicated to treat bacterial vaginosis ("BV").

3 Dec 2004

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

The two medicines (which are used in the treatment of AIDS) had been delisted by WHO in May this year due to non-compliance with international standards at the contract research organizations (CROs) hired by Cipla to conduct bioequivalence tests on the products.

30 Nov 2004

Novel anti-obesity compound shows promise for treatment of obesity

Arena Pharmaceuticals announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity.

30 Nov 2004

Rimonabant could be safer for treating obesity than previous weight-loss drugs

ECRI, a nonprofit health services research agency, recently published a Health Technology Forecast profile on a novel pharmaceutical agent that is in development for the treatment of obesity.

30 Nov 2004

Potential vaccine for the deadly toxin ricin

A potential vaccine for the deadly toxin ricin, a "Category B" biological agent, will enter the first phase of clinical testing in coming weeks at UT Southwestern Medical Center at Dallas.

30 Nov 2004

Biopharmaceuticals industry, a rapidly growing sector within the pharmaceuticals industry

Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.

30 Nov 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Manufacturers in the European active pharmaceutical ingredients market are struggling to overcome a variety of challenges

Manufacturers in the crowded and highly fragmented European active pharmaceutical ingredients (API) market are struggling to overcome a variety of challenges. One of the most pressing of these is the problem of overcapacity.

29 Nov 2004

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Forest Laboratories have announced that Combunox (Oxycodone HCl and Ibuprofen) Tablets (CII), the first and only fixed-dose combination of the opioid oxycodone HCl (5 mg) and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (400 mg), was approved by the U.S. Food and Drug Administration (FDA) for the short-term management of acute, moderate to severe pain.

29 Nov 2004

Pharmaceutical News

Chiron flu vaccine banned for a further three months

HHS purchases 1.2 million doses of GSK's Fluarix flu vaccine

Escalating costs and lengthy clinical trials are major concerns for researchers in the field of drug discovery

Prescription drug cost increases continuing to outpace inflation

ID Biomedical announces strategic alliances for U.S. marketing and distribution of Fluviral vaccine

Review findings released on the safety of antidepressants (SSRI's)

Alliance to develop and commercialize fully-human anti-anthrax antibody

Australian Government's decision to purchase sufficient influenza vaccine for the next three seasons is good health planning

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Pfizer submits regulatory filings for Revatio (sildenafil citrate) as a treatment for pulmonary arterial hypertension

A vitamin B pill that drastically lowers blood levels of homocysteine could one day be used to prevent dementia

FDA approval of cream to treat bacterial vaginosis

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

Novel anti-obesity compound shows promise for treatment of obesity

Rimonabant could be safer for treating obesity than previous weight-loss drugs

Potential vaccine for the deadly toxin ricin

Biopharmaceuticals industry, a rapidly growing sector within the pharmaceuticals industry

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Manufacturers in the European active pharmaceutical ingredients market are struggling to overcome a variety of challenges

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News